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Malaria is a major cause of morbidity and mortality in humans. Artemisinins remain as
the ﬁrst-line treatment for Plasmodium falciparum (P. falciparum) malaria although drug
resistance has already emerged and spread in Southeast Asia. Thus, to ﬁght this disease,
there is an urgent need to develop new antimalarial drugs for malaria chemotherapy.
Unlike human host cells, P. falciparum cannot salvage preformed pyrimidine bases or
nucleosides from the extracellular environment and relies solely on nucleotides synthe-
sized through the de novo biosynthetic pathway. This review presents signiﬁcant progress
on understanding the de novo pyrimidine pathway and the functional enzymes in the
human parasite P. falciparum. Current knowledge in genomics and metabolomics are
described, particularly focusing on the parasite purine and pyrimidine nucleotide meta-
bolism. These include gene annotation, characterization and molecular mechanism of the
enzymes that are different from the human host pathway. Recent elucidation of the three-
dimensional crystal structures and the catalytic reactions of three enzymes: dihydroorotate
dehydrogenase, orotate phosphoribosyltransferase, and orotidine 50-monophosphate
decarboxylase, as well as their inhibitors are reviewed in the context of their therapeutic
potential against malaria.1. Introduction
Malaria remains as one of the most deadly diseases in tropical
and subtropical endemic countries, with almost half of the world's
populations at risk of infection, estimated at 515 million clinical
cases and 1.3 million deaths annually [1–3]. Of the ﬁve
Plasmodium species that infect humans, including. Plasmodium
vivax (P. vivax), Plasmodium malariae, Plasmodium ovale, and
Plasmodium knowlesi, Plasmodium falciparum (P. falciparum)
is the causative agent of the most lethal and severe form of
malaria [1,4,5]. P. vivax, responsible for 25%–40% of the
estimated annual cases of malaria worldwide, is seldom fatal
but relapses often occur even after a primary infection has
cleared [6]. Over the past 50 years, the parasites' resistance toboth chloroquine and sulphadoxine-pyrimethamine has rapidly
emerged and is now widespread in the endemic countries [7].
Artemisinin and its derivatives, considered the most rapid
acting and efﬁcacious drug, are the ﬁrst-line drugs for treatment
of P. falciparum malaria [8]. However by 2009, resistance to the
drug treatment has been reported (Figure 1) [9]. Thus, it is
deemed necessary to develop novel antimalarial drugs for
malaria chemotherapy [10,11]. Applying lessons learned from
malaria research in the post-genomic era, together with
increased understanding in genomics, transcriptomics and pro-
teomics [12–16], this review highlights the candidate drug targets
for antimalarial drug discovery [11,17–20].
2. Genomics and metabolomics of malaria parasite
Most of the biochemical knowledge on P. falciparum has
focused on the intraerythrocytic life cycle of the parasite owing
to over 60 years of research [21–24], as well the established
cultivation method for these stages since 1976 by Trager and
Jensen [25]. With the availability of complete genome
sequences from various Plasmodium species such as, rodentess article under the CC BY-NC-ND license (http://
Figure 1. Geographic distribution of antimalarial drug resistant P. falciparum.
The resistance to two most widely used drugs, chloroquine and sulphadoxine-pyrimethamine, were represented in blue and yellow circles, respectively. The
artemisinin resistance, spreading over the mainland of Southeast Asia from Vietnam to Myanmar in 2014, was shown in black dash area.
Data were adapted from the WHO [7,9].
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(P. berghei), and Plasmodium chabaudi [27]; human malaria
parasites: P. falciparum [12], Plasmodium knowlesi [5], and
P. vivax [6], substantial genome information is now available
for comparative analyses. The genomes of the ﬁve human
Plasmodium species are relatively uniform, ranging from 23 to
27 Mb across 14 chromosomes, and comprising approximately
5500 genes, in which 51% of these have only one intron.
The G + C contents of P. falciparum and P. vivax genomes
are 19.4% and 42.3%, respectively. There are two
extrachromosomal genomes, the mitochondrion (a linear 6 kb-
DNA) and apicoplast (a circular 35 kb-DNA). From genomic,
transcriptomic and proteomic data for functional
reconstruction, the parasite's metabolic pathways are now
mapped in a public database [28,29]. Analysis of metabolic
pathways provides strong conceptual frameworks that allow
identiﬁcation of new drug targets resulting in acceleration of
preclinical candidates into the drug pipelines.
Several functional key metabolic pathways responsible for
survival of the parasite are identiﬁed: anaerobic glycolysis, a short
version of tricarboxylic acid cycle (Krebs' cycle), a simple
mitochondrial electron transport system (mtETS), pentose phos-
phate pathway, apicoplast fatty acid synthesis, phospholipid
synthesis, shikimate pathway, glyoxalate pathway, heme
biosynthesis, coenzymes A and Q biosynthesis, amino acid
metabolism, hemoglobin catabolism, vitamins B1 and B6 syn-
thesis, coenzyme folate biosynthesis, purine and pyrimidine
nucleotide synthetic pathways [7,12,28,29]. Pathways, most
relevant to the intraerythrocytic stages of the life cycle, have
unique properties. Some pathways are operated in two or three
different cellular components, e.g., heme biosynthesis
compartmentalizes in cytosol, mitochondrion and apicoplast
[30]. A number do not exist in the human host cells, e.g., folate
biosynthesis [31], which is a target of several antimalarial drugs(pyrimethamine, cycloguanil, sulphadoxine); hemoglobin
catabolism for required amino acid precursors as well as release
of potentially toxic heme. Other pathways are different from
human metabolism, for instance, the malarial type II fatty acid
synthesis that is similar to the bacterial pathway; and the purine
and pyrimidine nucleotide synthetic pathways [28,29].
3. Human and parasite purine and pyrimidine
nucleotide metabolisms
Nucleotide metabolism, one of the largest metabolic path-
ways in human cells, provides the building blocks for DNA and
RNA synthesis. The nucleotides are also key players in a wide
range of cellular functions, ranging from energy transduction,
signaling, syntheses of many biomolecules in carbohydrate and
lipid metabolisms [32]. Purine and pyrimidine nucleotides can be
provided from de novo biosynthetic pathways or supplied via
salvage pathways where nucleobases and nucleosides/
deoxynucleosides are recycled from nutrients or from
degraded DNA and RNA. In humans, both de novo and
salvage pathways are functioning at signiﬁcant levels for the
purine and pyrimidine nucleotide requirements, although the
salvage pathways were reported to be more active than the de
novo pathways [33,34]. This is true also for bacteria, plant and
the free-living nematode Caenorhabditis elegans [35–37].
The pathway itself plays an important role in the activation of
the nucleoside-based prodrug forms or analogs that can be used
in therapy or in itself serve as a drug target [38]. In rapidly
growing cells, including tumor and cancer cells, total cellular
purine and pyrimidine nucleotide pools are reportedly
imbalance suggesting therapeutic importance [39–41].
The mature erythrocyte, which provides the host environment
for P. falciparum growth and multiplication during the intra-
erythrocytic stages, has a relatively limited ability to salvage
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wise, the erythrocyte has no ability for de novo synthesis of
pyrimidines as inferred from the absence or very low levels for
enzymes involved in pyrimidine synthesis. In addition, there is
little activity of the salvage pathway for utilization of the py-
rimidine bases and nucleosides, uracil, uridine and thymidine,
eventhough both purine and pyrimidine nucleosides can be
taken up by the host erythrocyte [42].
In the intraerythrocytic stages of P. falciparum, only one of
the 10 enzymes for de novo synthesis of purine nucleotide,
namely adenylosuccinate lyase which is required to synthesize
inosine monophosphate (IMP) from the 5-phosphoribosyl-1-
pyrophosphate (PRPP) precursor has been identiﬁed [12]. This
enzyme also catalyzes the adenosine monophosphate (AMP)
synthesis from IMP in the purine salvage pathway. The
parasite relies on the salvage of purines or their precursors
from the human cell and plasma, particularly for hypoxanthine
which is the most abundant purine source in human blood and
regarded as the key precursor for other purines [43]. Thus, the
great majority of salvaged purine is funneled through
hypoxanthine to IMP by a broad substrate speciﬁc enzyme,
hypoxanthine-guanine-xanthine-phosphoribosyl-transferase
(HGXPRT). However, salvage of purine can also occur via the
sequential conversion of adenosine to inosine and hypoxanthine
by adenosine deaminase (ADA) and purine nucleoside
phosphorylase (PNP), respectively. Adenosine is known to be
rapidly imported into the parasite by at least two effective
transporters [43–45]. Moreover, ADA is able to use
methylthioadenosine from the polyamine biosynthetic pathway
to produce methylthioinosine, which is then catalyzed to
hypoxanthine by PNP [43–45]. Thus, the parasite ADA
functions at the intersection of polyamine metabolism and
purine salvage pathway.Figure 2. Purine salvage pathway and interconversion of purines in P. falcipa
Red and green arrow indicated predominant and minor pathways, respectively
biosynthesis in the parasite. Numbered enzymes were as follows: 1, ADA;
adenylosuccinate synthase; 5, adenylosuccinate lyase; 6, nucleoside monoph
ibosyltransferase; 9, IMP dehydrogenase; 10, GMP synthetase. Figure adaptedIn order to obtain adenylate nucleotides, IMP is ﬁrst cata-
lyzed by adenylosuccinate synthetase to adenylosuccinate
(AMPS), which is then converted to (AMP) by adenylosuccinate
lyase. To get guanylate nucleotides, IMP dehydrogenase cata-
lyzes the conversion of IMP to xanthosine monophosphate
(XMP), which is then converted to guanosine monophosphate
(GMP) via a predominant route for GMP production by GMP
synthetase. HGXPRT is also able to catalyze, albeit with limited
activity, the conversion of xanthine base to XMP and guanine
base to GMP [45,46]. The current understanding on purine
salvage pathway and interconversion of salvaged purine
derivatives to provide ATP, dATP, GTP and dGTP for the
synthesis of DNA and RNA nucleic acids, and the linkage of
polyamine and purine pathways are summarized in Figure 2.
Details of the parasite transporters that allow reutilization of
preformed purine nucleosides and bases, the enzymes involved
in the purine salvage pathway, including known three-
dimensional crystal structures of these enzymes in
P. falciparum have been recently reviewed [43,44].
4. Malaria parasite de novo pyrimidine biosynthetic
pathway
The de novo pyrimidine biosynthetic pathway represents one
of the oldest and most conserved metabolic pathway, and the six
sequential enzymatic steps starting from bicarbonate (HCO3
−),
glutamine (Gln), and ATP, producing uridine 50-monophosphate
(UMP) (Figure 3), have remained intact throughout evolution,
although the primary structures of the enzymes responsible for
the synthesis deviate signiﬁcantly among prokaryotes, parasitic
protozoa, fungi, animals, and mammals including humans [47–
51]. As emphasized above, unlike human cells, P. falciparum
parasites have little ability to salvage preformed pyrimidinerum.
: blue arrow showed polyamine reaction that links purine and polyamine
2, PNP; 3, hypoxanthine-guanine-xanthine-phosphoribosyl-transferase; 4,
osphate kinase; 7, nucleoside diphosphate kinase; 8, adenine phosphor-
from [42].
Figure 3. Schematic view of six sequential enzymatic reactions for de novo pyrimidine biosynthesis in P. falciparum.
The enzyme CA was proposed to be associated with the pyrimidine pathway. The mtETS was linked to the enzyme DHOD of the pathway, functioning as
electron disposal. NMPK, nucleoside monophosphate kinase.
Table 1
First six enzymes of de novo pyrimidine biosynthesis in two malaria
parasites, P. falciparum, P. berghei, vs host erythrocytes.a
Activity (units per mg protein
of crude extract)
Reaction step Enzyme P. falciparum P. berghei Erythrocyte
1 CPSII 0.04 0.46 <0.01
2 ATC 11.10 7.24 <0.05
3 DHO 0.22 0.44 <0.01
4 DHOD 0.10 0.42 <0.01
5 OPRT 25.37 1.60 <0.05
6 OMPDC 20.86 1.85 <0.05
a
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mostly on nucleotide synthesized through the de novo pathway.
Evidence for a functional pyrimidine de novo synthesis in the
intraerythrocytic stages comes largely from the following lines
of investigation. First, in vitro cultures of P. falciparum incor-
porate radioactive HCO3
− into pyrimidine bases of DNA and
RNA. The parasite demonstrates very little incorporation of
radioactive orotate, uracil, uridine, thymine and thymidine into
its DNA and RNA, whereas the pyrimidines were easily taken
up by the P. falciparum-infected erythrocytes [21,22]. Second,
although most of the enzymes responsible for salvaging
preformed pyrimidine bases and nucleosides have been
identiﬁed, their activities appears to be low, e.g., thymidine
kinase, cytosine kinase, uridine kinase, uracil
phosphoribosyltransferase. There is one exception – the
enzyme uridine phosphorylase (UP), required to add ribose
from ribose-1-phosphate to uracil for uridine production. The
enzyme was identiﬁed in both P. falciparum genome (locus:
PFE0660c) and the parasite extract [12,52]. The primary structure
of the parasite UP suggests that it is one of the moonlighting
proteins having both UP and PNP activities on the same
polypeptide [53]. Third, all the enzymes required for de novo
synthesis of UMP, the ﬁrst pyrimidine nucleotide metabolite
acting as the precursor for synthesis of all pyrimidine
nucleotides including CTP, dCTP, TTP, and dTTP, were
detected in cell extracts from all Plasmodium species so far
examined (Table 1) [54–56]. Finally, the genes encoding each
enzymes in all steps of the de novo pathway were detected,
whereas most genes for the pyrimidine salvage pathway were
conspicuous by their absence with the exception of pfUP gene
[12,28,29].
The pyrimidine genes (pyr1 = pfCPSII, pyr2 = pfATC,
pyr3 = pfDHO, pyr4 = pfDHOD, pyr5 = pfOPRT, andpyr6 = pfOMPDC) encoding the ﬁrst six enzymes of the pathway
were identiﬁed in the P. falciparum genome [12]. The pyr1–pyr6
open reading frames (ORFs) are organized on different locations
at various chromosomes: pfCPSII encoding carbamoylphosphate
synthetase II (CPSII) and pfATC encoding aspartate
transcarbamoylase (ATC) on chromosome 13, pfDHO encoding
dihydroorotase (DHO) on chromosome 14, pfDHOD encoding
dihydroorotate dehydrogenase (DHOD) on chromosome 6,
pfOPRT encoding orotate phosphoribosyltransferase (OPRT) on
chromosome 5 and pfOMPDC encoding orotidine 50-
monophosphate decarboxylase (OMPDC) on chromosome 10.
The location and organization of all six pyrimidine genes are
summarized in Table 2. The parasite pyrimidine genes have the
following characteristics: 1) single ORF, having no intron, 2)
single copy, and 3) the loci are close to the hypothetical proteins on
the chromosome. The genes are separated from each other and are
not operon-like in its molecular organization. This property differs
from its analogous parasitic protozoan Trypanosoma andData were taken from [42,86].
Table 2
Organization and character of de novo pyrimidine genes and their enzymes in P. falciparum.a
Gene Chromosome Locus Size (bp) Enzyme form Amino acids (residues)
pyr1 (pfCPSII) 13 PF13_0044 7329 Monob 2391
pyr2 (pfATC) 13 PF13_0240 1435 Mono 339
pyr3 (pfDHO) 14 PF14_0697 1076 Mono 358
pyr4 (pfDHOD) 6 MAL6P1.36 1709 Mono 569
pyr5 (pfOPRT) 5 PFE0630c 846 Complexc 281
pyr6 (pfOMPDC) 10 PF10_0225 972 Complex 323
a Data were taken from [52]. b Monofunctional enzyme. c Heterotetrameric OPRT-OMPDC enzyme complex.
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or synteny constituting of a polycistronic transcript unit on a 25 kb
segment of the 800 kb chromosomal DNA [49,50]. The malarial
pyrimidine genes are also different from humans in that the
fused and single gene pyr1–pyr3–pyr2 (locus: 2p22–21) encodes
the multifunctional CAD protein catalyzing the ﬁrst three
enzymes activities and the gene pyr5–pyr6 (locus: 3q13)
produces the bifunctional UMP synthase activity (Table 3) [47–
49]. In addition, the human pyr4 gene is located separately at
locus 16q22. In prokaryotes, pyr genes may be localized on
different loci as in the bacterial chromosomes, e.g., Escherichia
coli (E. coli) [35]; or may be clustered as an operon similar to
Bacillus subtilis pyr genes which are transcribed on one large
polycistronic message in the 12.5 kb of Bacillus subtilis
chromosomal DNA [48].
The identiﬁed ORFs of the pyr1–pyr6 genes of P. falciparum
are deduced from amino acid sequences of the pyrimidine en-
zymes. Using multiple sequence alignments and phylogenetic
analyses the enzymes pfCPSII, pfDHO and pfOPRT are
conserved to bacterial counterparts. The malarial pfATC,
pfDHOD and pfOMPDC are mosaic variations, which are ho-
mologous to both bacterial and eukaryotic counterparts,
including humans. ATC sequence comparison with Toxoplasma
gondii, a parasitic protozoan, reveals only 30% identity to the
pfATC gene. The pfDHO sequence is close to most bacterial
sequences, the yeast Saccharomyces cerevisiae and the plant
Arabidopsis thaliana, indicating that P. falciparum may carry
the monofunctional DHO gene acquired thru horizontal gene
transfer from a proteobacterium, e.g., E. coli, Neisseria gonor-
rhoeae [52].
In the malaria parasite, there is relatively little information on
the sequential enzymatic steps after UMP synthesis before
yielding dCTP, dTTP, CTP, TTP which are the building blocks
for DNA and RNA synthesis (Figure 3). Genes are present in the
parasite genome but few enzymes have been studied to date.
P. falciparum ribonucleotide reductase (RNR) catalyzes theTable 3
Organization and molecular property of de novo pyrimidine genes and theirs
Gene Chromosome Locusa Gene chara
pyr1 2
pyr2 2 2p22-21 pyr1-3-2c
pyr3 2
pyr4 16 16q22 Separated
pyr5 3
pyr6 3 3q13 pyr5-6
a NCBI database accession number: MIM: 114010, MIM: 274270, MIM: 25
in the order of pyr1-3-2.production of deoxyribonucleotides from ribonucleotides, which
is associated with thioredoxin reductase [57–59]. TMP kinase
(TMPK), catalyzing the synthesis of dTTP and TTP, is known
as type I enzyme by amino acid sequence but has high
efﬁciency in phosphorylation of 30-azido-30-dTMP as well as
E. coli type II TMPK [60]. Notably, the parasite TMPK can
also phosphorylate dGMP and dUMP with high speciﬁcity,
indicating a broad spectrum of substrate speciﬁcity [61].
However, CTP synthetase (CTPS) which catalyzes the
formation of CTP from UTP, is the only known enzyme for
cytosine nucleotide de novo synthesis in the parasite [62–65].
In P. falciparum, the de novo pyrimidine pathway is closely
linked to the folate biosynthesis by the thymidylate synthetase
(TS) (Figure 3) [66]. The parasite TS is a part of the bifunctional
dihydrofolate reductase-thymidylate synthase (DHFR-TS), a
validated target for antifolate drugs [67]. The three-dimensional
crystal structure of the P. falciparum enzyme and substrate
channeling domains have been resolved [68]. It is well
recognized that the de novo folate pathway is operating in the
parasite, like in bacteria, whereas the human host is incapable
of de novo synthesis. In addition, the parasite also has ability
to salvage preformed folates from the human host [66,69].
5. Malarial CPSII, ATC and DHO are
monofunctional enzymes
Progress towards understanding structures, catalytic mecha-
nisms and regulation of mammalian and human enzymes for de
novo pyrimidine pathway has been signiﬁcant in recent years
[32,51]. Certain key differences of the enzymes, pathway, and
their genomes including the six enzymes of the pathway from
precursors HCO3
−, Gln, and ATP to UMP synthesis warrants a
closer look.
By using analytical gel ﬁltration chromatography, the ﬁrst
three enzymes (CPSII, ATC, and DHO) of the rodent parasite
P. berghei were readily separated into three different molecularenzymes in human.
cter Enzyme form Molecular massb (kDa)
Fused
Trifunctional CAD 243
Monofunctional 43
Fused
Bifunctional UMPS 52
8900. b Data were taken from [51]. c Genes pyr1, pyr2, pyr3 were fused
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discrete monofunctional proteins. This is similar to that found
in another species of protozoa, Crithidia fasciculata, and in
many prokaryotic systems [35,70]. The characteristic differs
from the humans wherein the CPSII, ATC and DHO activities
are carried on a 243-kDa multifunctional protein, called CAD
[47].
The malarial DHO enzyme has been puriﬁed from
P. falciparum and its gene has been cloned, expressed and
characterized in detail by our groups [71]. It is a Zn2+ enzyme
belonging to the amidohydrolase family, sharing characteristics
of both mammalian type I and eubacterial type II DHO by
overall amino acid sequence homology, structural properties,
kinetics and inhibitor characteristics [71–73].
In mammals, the CPSII domain of the CAD is a rate limiting
step of the pathway, which is subject to UTP feedback inhibition
and allosteric activation by PRPP [39–41]. Responses to allosteric
effectors are modulated by phosphorylation, through signaling
cascades of mitogen-activated protein kinase (MAP kinase)
and protein kinase A (PKA) when demand of the pyrimidine
nucleotides is greatest; and by protein kinase C (PKC) when its
demand is least [51]. In the bacterial system, the ATC activity is
sensitive to feedback inhibition by CTP, and is activated by ATP
using allosteric regulation [35]. At present, the malarial CPSII
and ATC enzymes are still poorly characterized and regulation
of these pyrimidine enzymes is largely unknown.
6. Malarial DHOD is the mitochondrial enzyme
Numerous studies have focused on DHOD, the fourth
enzyme in the pathway, particularly as a target for antimalarial
agents [74–78]. The P. falciparum DHOD gene has been cloned,
expressed and characterized [79]. Immunogold labeling localized
DHOD in the inner membrane of mitochondrion [77]. The three-
dimensional crystal structure of the parasite enzyme has been
elucidated and compared to the human DHOD structure [80,81].
Crystal structures of human and parasite DHOD identiﬁes
completely different binding sites for the inhibitor leﬂunomide.
The overall structure is a/b-barrel, similarly to that of other
family 2 DHOD of eukaryotic origin (Figure 4A). It contains
ﬂavin mononucleotide prosthetic group, ubiquinone binding site
and active site for dihydroorotate substrate, consistent with the
previous assumptions using kinetic analyses [76,77]. Furthermore,
the pyrimidine pathway is linked to the mtETS through theFigure 4. Three-dimensional structure of three P. falciparum enzymes: DHOD
All structures were a/b-barrel, with a-helix shown in violet and b-strand show
triazolpyrimidine inhibitor. OPRT and OMPDC were in dimeric forms as apoen
with PDB ID: 5DEL, 4FYM, and 2ZA2, respectively. The models were builtDHOD and ubiquinone coenzyme [77]. The mtETS are
valuable targets in malaria chemotherapy [30,82–85].
7. Malarial OPRT and OMPDC are multienzyme
complex
We characterized the functional, kinetic, and structural
properties of OPRT and OMPDC, the ﬁfth and sixth enzymes of
the de novo pathway [86–88]. The OPRT and OMPDC enzymes
were puriﬁed directly from P. falciparum culture. The native
enzymes are organized in an a2b2 heterotetramer structure
having two subunits each of OPRT and OMPDC [86]. We also
expressed both genes in E. coli [87,88]. Co-expression recombi-
nant P. falciparum OPRT and OMPDC genes also exhibited the
a2b2 complex formation [89,90]. Most recently the parasites' low
complexity region was found to be responsible for the protein–
protein interaction in the heterotetrameric formation of the
malarial OPRT and OMPDC enzymes, [(OPRT)2(OMPDC)2],
as identiﬁed by means of a unique insertion of low complexity
amino acid sequence characterized by single amino acid repeat
which was not seen in homologous proteins from other
organisms (Figure 5) [91]. The steady-state kinetics of initial
velocity and product inhibition studies of the monofunctional
OPRT and OPRT domain in the heterotetrameric complex fol-
lows a random sequential kinetic mechanism [87,89].
Furthermore, three-dimensional crystal structures of the
parasite OPRT and OMPDC have been elucidated (Figure 4B
and C) [92–95] and compared to the recently characterized human
OPRT and OMPDC structures [32]. Direct decarboxylation
mechanism for OMPDC catalysis was proposed based on the
crystal structures of the OMPDC-OMP substrate and OMPDC-
UMP product complexes. In this catalytic mechanism, the
decarboxylation of OMP is initiated by charge repulsion be-
tween the C6 carboxylate group of OMP and the carboxyl group
at the side chain of Asp136, followed by a proton transfer from
Lys138 to the C6 position of UMP, and Lys102 hydrogen
bonded to Asp136 instead of the carboxyl group of the pyrim-
idine ring after decarboxylation. There is a strong network of
charged residues around the C6 position that has the potential to
destabilize the ground state and stabilize the transition state for
the decarboxylation of OMP [93]. By far, the inhibitors of
OMPDC have been designed and chemically synthesized for
therapeutic potential against malaria using the structure-based
drug-design approach [94,96,97].(A), OPRT (B), and OMPDC (C).
n in gold. The DHOD, as monomeric form, was in complex with DSM265
zyme. The DHOD, OPRT, and OMPDC were taken from Protein Data Bank
using the Java program.
Figure 5. Sequential steps for dimer and tetramer formation of P. falciparum OPRT and OMPDC. The inactive monomer OPRT and OMPDC form its
homodimer (OPRT)2 and (OMPDC)2. Both homodimers are then associated into heterotetrameric [(OPRT)2(OMPDC)2] complex. The OPRT and OMPDC
models are shown in red and blue, respectively.
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pyrimidine pathway in the parasite
Functional and kinetic properties of CA were performed from
P. falciparum [98]. The parasite CA catalyzes the interconversion
of HCO3
- and CO2 possessing catalytic properties distinct from
that of the human host CA isozymes I and II. Low amino acid
sequence identity in the primary structures and phylogenetic
analyses is being tapped for malaria chemotherapy, which is
now in preclinical phase for drug development [99–101]. The
CA supplies HCO3
− as substrate for the CPSIIof the de novo
pyrimidine synthetic pathway, linking the parasite CA to the
pyrimidine pathway (Figure 3) [102–104].
9. Concluding remarks and future prospects
Until very recently, artemisinin-resistant parasites have
spread over the mainland of Southeast Asian from Vietnam to
Myanmar (Figure 1) [105]. The emergence and spread of these
parasites entails novel measures for malaria treatment and
control. Hopefully, one inhibitor, namely DSM265 (a
triazolopyrimidine compound (Figure 4A)), targeting the
DHOD enzyme of the pyrimidine pathway would prove prom-
ising as it progresses to preclinical and clinical phase I trials for
drug development [106,107]. Moreover, as structure-based design
of antimalarial drug development continues to tapped X-ray
crystal structures of the enzyme, in silico screening and surface
plasmon resonance analysis, especially for the parasite OMPDC
[94], the possibility of modulating potential toxicity through the
biochemical pathway might have therapeutic potential against
human malaria [108].
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